Scuttlebutt
Cancel
Sign in
Companies
Investors
Fund letters
Experts
Media
Newsletters
Books
Papers
Updates
Feedback
Settings
Scuttlebutt
×
Companies
Investors
Fund letters
Experts
Media
Newsletters
Books
Papers
Updates
Feedback
Settings
Dark mode
Updates
×
22 Nov
137 new fund letters and reports, each with its own page: Kayne Anderson Rudnick (48 market briefings, KayneCast episodes and TV commentaries), Shelton Capital Management (48 shareholder reports and a commentary), Lakehouse Capital (10 Small Companies Fund letters), Smead (5 newsletters), RIT Capital Partners (5 monthly commentaries), Kovitz, Legal & General, Generation, Hosking, Marram, Munro, Oldfield and others.
21 Nov
200 new fund letters and reports, each with its own page: Spheria (41 monthly reports), Peapack Private (41 weekly recaps and planning newsletters), Fort Washington (23), Polen Capital (15), Aristotle Pacific (14), Riverwater (13), Chou (10), Apollo Asia Fund (8, back to 1998), Personal Asset Trust, Rockwood Strategic, J Capital Research, I/O Fund, Penn Davis McFarland, Pomona and others.
20 Nov
Investor pages have one Investments tab with shares, changes, % owned, class, market cap and Market cap and Status filters, a Funds tab listing each fund the firm runs, and assets under management from Form ADV. The Investors table shows AUM and current investments, and its search finds investors by what they hold.
20 Nov
Filters, search and sort stay as you left them when you come back to a section. Person cards look like book cards. Company pages name their Investors tab Ownership. Kind and Sector filters use four kinds and GICS sectors with industries. Dead links left the Links tabs.
20 Nov
190 more investors from fiscal.ai's list, with their sites, letters, partners and 13F holdings; 556 more partner descriptions. Experts now lists only people.
20 Nov
Fund letters lists 144 new documents from 23 firms, each with its own page: a summary, key insights and quotes. Among them: 37 BlackRock articles, 21 Value Partners monthly notes, eight Baron Capital letters, six Stone Sentinel letters to partners, seven Value Line portfolio manager Q&As, BNY's 2026 earnings releases and Starboard Value's 2026 conference presentations.
20 Nov
584 more investors, with their websites, 6,776 letters from their own sites, 1,385 partners with pages and the 13F holdings of 213 firms. New letters arrive daily from 290 more archives.
19 Nov
Media and Companies filter by GICS sector and industry group, taken from the companies an episode or page names. 1,860 more company pages show a logo, the SEC's list included.
19 Nov
The home page counts what the platform holds and lists features such as the document reader, the player and saved marks. Settings sits at the foot of the rail. Book cards are a quarter wider, so rows hold fewer. Companies drops the Named in filter, and the Role list in your account runs A to Z.
19 Nov
Investor pages of 13 firms show their newsroom's latest posts. New 13F filings are read as the SEC publishes them.
19 Nov
Investor pages have an Investments tab: 13,975 holdings for 105 investors, from their 13F filings with the SEC and their own portfolio pages, with status and sector. 7,338 more companies have a page of their own.
19 Nov
A podcast or YouTube episode keeps playing while you move around the site, in a bar with skip, speed and volume. Media tables show each episode's length and description.
19 Nov
Press releases come from each company's own newsroom (167 companies); SEC filings sit on the Filings tab. Tickers name their exchange, and a company's Experts tab includes guests whose episode description names it.
19 Nov
Letter types now include Market commentary, Fact sheet, Interim report, Annual report, Proxy circular and Governance document. The reader opens over the whole window.
19 Nov
Partners of investment firms have 2,836 appearances and 580 pieces of writing on their pages; Derek Sivers's page lists every book he rates, with his rating.
19 Nov
Fund letters lists three Akre Focus shareholder reports: the ETF's annual report for the year to July 2026, its semi-annual report to January 2026 and the fund's semi-annual report to January 2025, each with its own page: a summary, key insights and quotes.
19 Nov
837 partners of 73 investment firms now have their own pages, with title, description, photograph and social accounts; Andreessen Horowitz partners' pages also list their writing on a16z.com.
19 Nov
Company pages have a Press releases tab: 8,229 releases for 203 companies, from SEC filings and company newsrooms. Companies filter by For-profit or Non-profit. Own media is a table with filters. Media filters by sector and industry. Publication pages link their publisher in the description.
19 Nov
The Unilever page's Letters tab shows what each fund letter says about Unilever, word for word with its page, and whether the letter is bullish, bearish, mixed or neutral. Filter by sentiment, and see 10 letters at a time.
18 Nov
492 more fund letters and 3,183 more articles show the day they were published, read from each letter's first page or each article's own page.
18 Nov
The PDF reader has a search box: type words to see every match in the document and step through them. About 540 letters that were web pages, among them Oakmark's commentaries, Bill Miller's letters and Howard Marks's memos, now open in the reader.
18 Nov
Person pages: recommendations open with tier 1 books; one button per organisation; transcripts sit on their episodes; the books on 129 reading lists joined the Recommends tabs.
18 Nov
Companies lists every company with a ticker on the SEC's list, with a Source filter. A quote on a company page opens the letter at that page with the words marked. A company's Media tab lists only episodes that name it, and a new Own media tab lists its podcasts, publications and YouTube channel. Show pages link their publisher. A page opened from a table no longer shows that table's filters beside it.
18 Nov
Company, investor and person pages show more of their social accounts: Facebook, TikTok, Bluesky, Medium, GitHub, Discord and podcast shows. Investor pages list every partner the firm's own team page names: 965 people across 73 investors, 98 for Andreessen Horowitz.
18 Nov
About 170 more letters and papers open in the reader: Mohnish Pabrai's letters and transcripts from his site's new folder, and free copies of papers by Asness, Harvey, Altman, Lo and others from their own or their schools' sites.
18 Nov
Every company a fund letter names has a page, with the letters and quotes that name it: 47 new pages, among them Atom Computing, Hugging Face, Rolls-Royce Holdings and Westinghouse Electric. Company pages have a Quotes tab.
18 Nov
A person's Writing tab has a Type column and filter (Article, Essay, Transcript, Speech, Foreword, Interview and the rest), and Publication names only the publication that published each piece.
18 Nov
Fund letters opens on the newest published letter, and a letter or paper found by search opens its own page here instead of the publisher's site.
18 Nov
A letter or paper with a copy on the site opens its PDF over its page, with a button to open it in a new tab. Select text to highlight or underline it; signed-in readers keep their marks in their account. Each quote opens the PDF at its page with its words marked, and a Source link leads to the publisher's original.
18 Nov
Fund letters lists 61 more documents, each with its own page: Fairfax's 2025 and 2026 interim reports, proxy circulars and 2025 annual report (with their French editions), 26 Charlie Munger meeting transcripts, talks and essays, Third Point's 2026 monthly reports and Malibu Life's interim results, and a Seth Klarman interview. Papers adds Richard Thaler's two 2020 editorials on nudges.
17 Nov
Fund letters lists Lux Capital's letters for Q2 and Q3 2026, by Josh Wolfe, each with its own page: a summary, key insights and quotes.
13 Nov
Fund letters lists Brookfield's letter to shareholders for Q3 2026, by Bruce Flatt, with its own page: a summary, key insights and quotes.
12 Nov
Fund letters lists Howard Marks's memo of 11 November 2026, A Layman Thinks About AI, with its own page: a summary, key insights and quotes.
11 Nov
Fund letters lists 118 more letters, each with its own page: 44 weekly commentaries by Jeremy Siegel from 2026, 31 issues of Van Tharp's newsletter from 2018, 23 Pabrai Investment Funds letters from 2021 to Q3 2026, 13 Efficient Frontier essays by William Bernstein, Oakmark's three 3Q 2026 commentaries, two Lindsell Train reports, a John Hussman comment and Third Point's Q3 2026 letter.
11 Nov
2,027 more books carry a one-line description in the Books table and on their pages; 7,067 of 7,715 have one, every tier 1, 2 and 3 book among them.
11 Nov
Fund letters lists 187 more letters from 19 firms, among them Permanent Equity, Social Capital, Lux Capital, Square Peg, Bestinver, Cobas, Sequoia Fund, Marketfield and EquityCompass; each shows on its investor's page and has a page of its own.
11 Nov
2,928 more books carry a one-line description in the Books table and on their pages, so every tier 1, 2 and 3 book has one; 5,040 in all.
11 Nov
Every publication on Newsletters has its own page: its writing, its writers, its staff and who recommends it. Investor pages have a Management tab; a company's Experts tab now leaves out its own people, who list under Management. Tabs on a phone move sideways only.
11 Nov
Every fund letter and research paper has its own page: the thesis, the PDF, the companies and books it names, and for 176 letters and 24 papers so far a summary, key insights and quotes with their page.
11 Nov
99 books that no page listed now sit under their topics in Books, among them Caste, American Prometheus and Pale Blue Dot.
11 Nov
Newsletters lists every newspaper, magazine, investment newsletter, journal and blog the reference holds, 442 in all, with the people who write there. The search box keeps your last 20 searches. You can create an account.
11 Nov
283 books that fund managers recommend in their letters are on the shelf, each with the letter's own words and page; investor pages have a Recommends tab.
10 Nov
Person, company, investor and show pages link their own accounts on X, Threads, Instagram, LinkedIn, YouTube and Substack: 275 people, 552 companies and organisations, 88 investors and 478 shows.
10 Nov
716 more book recommendations name their source: the person's own reading list, letter, blog post, speech or interview, or an article that reports it. 232 of them quote the person's own words about the book, on the book card and on the book's page.
5 Nov
Every US-listed company has a page with its SEC filings. Company pages list their experts and their management, past and present. Fund managers sit under Investors. Each show has a page of its episodes, and an episode page names its guests and hosts. Biographies lists groups, then people. Breadcrumbs show where a page sits.
5 Nov
Media lists every podcast episode, video, interview and talk, over 10,000, by person, company, publisher and event; each filter searches its own choices. Books opens on its table, then Browse, then Authors and Recommenders. A filter's count no longer covers its arrow.
5 Nov
A book that no company, country or subject page lists shows its topics under Where it sits in the reference. On a phone, a page's tabs scroll sideways only. Descriptions read the same on every page. See them in the Experts tab lists every expert the page names.
5 Nov
Every podcast episode, video and interview has its own page with a video or audio player and a link to the source. Investor pages show each company's sector and market cap; firms such as Berkshire Hathaway have one page that holds their letters and their company tabs. Letters tabs filter by company and search the theses. Companies filter by Public, Private and Defunct and link each company's website.
5 Nov
Every tab, view and search has its own address, such as /books/table/asset or /letters/companies, so Back works and a link opens the same place. Page addresses no longer end in .html. Fund letters, Investors, Companies and Papers load about a fifth of the data they did.
3 Nov
Fund letters has a Companies tab: every company the letters name, with its market cap, sector, country, and how many letters and investors name it. Investor pages link each investor's website. Lists in table cells end with “… and N more” at every width.
3 Nov
1,120 more book summaries; descriptions for 373 papers; pages for 137 more companies, each with the fund letters that discuss it; 215 official photographs; search has its own page.
3 Nov
411 more books have a summary; person pages list 930 more of the books they wrote; 147 people show their official photograph.
3 Nov
Every investor has a page with its letters and the companies they discuss; company pages list the investors whose letters name them.
3 Nov
A Companies section at the top of the rail lists every company the books, experts and fund letters name.
3 Nov
Person pages list letters, writing, profiles and links as sortable tables with filters, and show each person's companies as links; Fund letters show each letter's description in its own column.
3 Nov
Experts show a checked job title and a short description of each person; 30 more people have photographs.
3 Nov
Every company, fund, university and publication the experts work for has a page listing the people there.
3 Nov
Fund letters show each letter's thesis and filter by it; 225 person pages list the essays, columns and newsletter issues the person wrote.
1 Nov
Person pages list every essay and newsletter issue a person wrote, and their own books as a table in List view.
1 Nov
Recommends shows the five largest kinds of book and the rest under More; browse pictures load sooner.
29 Oct
Podcasts and talks link the original episode, filter by Audio and video or Press, and list each publisher once.
29 Oct
Pages are wider, Recommends has List and Grid, and a filter clicked again turns off.
28 Oct
Book cards sit in a ruled grid with Open Library and Goodreads links and each book's one-line note.
28 Oct
Funds is now Investors; each investor's styles are buttons that filter the table.
28 Oct
Podcasts and talks on a person's page filter by year and publisher and show as a list or a grid of pictures.
28 Oct
Quotes show only people's own words: 472 summaries written by list sites are gone.
27 Oct
Country pages open from Browse again, and every link on the shelf lands on a page.
27 Oct
Subject and person pages show their sections as tabs, and each book appears once on a person's page.
27 Oct
Book cards show the quote, who said it and the source; grids show five cards to a row.
27 Oct
On a phone, a menu holds the sections, search, Updates, Feedback and dark mode.
25 Oct
Feedback takes a screenshot of the page with no browser prompt, opens a screenshot full size when you click it, and clears itself once sent.
25 Oct
Book cards are centred, search names the topic each book sits in, and any text cut short shows whole on hover.
23 Oct
Search groups its results by kind: people, companies, geographies, subjects, topics, books, funds, fund letters and papers.
23 Oct
The Books table lists who recommended each book by name, and the browser tab names the section you are in.
23 Oct
Feedback can take a screenshot of the page, or one you paste or choose, and opens in the corner beside Updates.
23 Oct
Each rail button reopens its section where you left it, and Browse, Table and People show on every book and subject page.
23 Oct
Filters grey out choices that hold nothing instead of hiding them, and Books › People filters by authors or recommenders.
23 Oct
Feedback takes a subject line and up to three screenshots.
22 Oct
Biographies are grouped by the person they are about: 41 new pages, from Abraham Lincoln to Lee Kuan Yew.
22 Oct
Sport splits into 23 sports, and Religion into one topic per faith.
22 Oct
Book lists show as cards: the cover, one recommendation quote and every recommender by name.
22 Oct
Seventeen subjects that had two or three pages under different names now have one page each.
22 Oct
Every page lists its Experts as authors and recommenders, with a link to them on the Experts tab.
22 Oct
Economics, Financial history, Financial panics and Accounting are subjects of their own, with one page per financial crisis.
22 Oct
Book, person and subject pages open inside the app, so the tabs stay in view.
22 Oct
996 more book covers, and photographs or logos for 227 more people and companies.
21 Oct
Books › Browse shows every subject as cards, and the rail holds Fund letters, Papers, Experts, Books and Funds.
20 Oct
Every topic over 150 books splits into narrower topics, each with a page of its own.
Send feedback
×
What is it?
Report an issue
Feedback or feature request
Subject
Message
Screenshots, up to 3 (optional)
Take a screenshot
Choose a file
or paste one with
Ctrl
+
V
Your email
We use your email only to reply to you.
Cancel
Send
Companies
›
Arresto Biosciences
Arresto Biosciences
company
Healthcare
Cancer drug discovery biotech
Source
gilead.com ↗
Ownership
1
Press releases
50
Investor
Managers
Letters
Years
Holding
Kleiner Perkins
0
Acquired by Gilead
Title
Published
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
16 Nov 2026
Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
12 Nov 2026
New Data Show Twice Yearly Lenacapavir Achieved Nearly Twice the One Year Persistence of Daily Oral F/TDF in HIV Prevention
6 Nov 2026
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
5 Nov 2026
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
4 Nov 2026
Gilead to Present Late Breaking Clinical Data and Real World Evidence at HIV Glasgow
2 Nov 2026
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
30 Oct 2026
Gilead Sciences Announces Third Quarter 2026 Financial Results
29 Oct 2026
Gilead to Acquire Investigational Oral IL 23R Inhibitor HCXT 2001, Strengthening Its Inflammation Pipeline in IBD
22 Oct 2026
Gilead to Present New Data on Treatment Response and Long Term Management of Rare Liver Diseases at The Liver Meeting® 2026
22 Oct 2026
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
19 Oct 2026
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
15 Oct 2026
Gilead Accelerates Global Access Planning for Investigational Once Yearly Lenacapavir for HIV Prevention
16 Sep 2026
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
15 Sep 2026
Gilead Opens State of the Art Research Center to Advance the Next Generation of Medicines
8 Sep 2026
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
27 Aug 2026
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
26 Aug 2026
European Commission Expands Role of Gilead’s Trodelvy® in First Line Metastatic Triple Negative Breast Cancer Across PD L1 Status
24 Aug 2026
Gilead Sciences Announces Second Quarter 2026 Financial Results
5 Aug 2026
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD (L)1 Positive First Line Metastatic Triple Negative Breast Cancer
24 Jul 2026
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21 Jul 2026
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
21 Jul 2026
Investigational Once Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
21 Jul 2026
U.S. FDA Approves Trodelvy® for First Line Treatment of Metastatic Triple Negative Breast Cancer
24 Jun 2026
European Commission Approves Trodelvy® as a First Line Treatment for Metastatic Triple Negative Breast Cancer Patients Not Candidates for PD (l)1 Inhibitors
23 Jun 2026
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once Weekly HIV Treatment
19 Jun 2026
U.S. FDA Accepts Gilead’s Application for Investigational Once Weekly Oral Yeztugo, Potentially the First Long Acting Pill for HIV Prevention
15 Jun 2026
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade Long Commitment to Outbreak Relief
12 Jun 2026
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
11 Jun 2026
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
8 Jun 2026
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
5 Jun 2026
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
4 Jun 2026
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
2 Jun 2026
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
27 May 2026
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
22 May 2026
Gilead Receives CHMP Positive Opinion for Trodelvy® in First Line Metastatic Triple Negative Breast Cancer for Patients Not Candidates for PD (L)1 Inhibitors
22 May 2026
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
21 May 2026
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
21 May 2026
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody Drug Conjugates and Cell Therapy in Oncology
21 May 2026
Gilead Prices $3 Billion of Senior Unsecured Notes
15 May 2026
Gilead Prices $3 Billion of Senior Unsecured Notes
15 May 2026
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
13 May 2026
Gilead Sciences Announces First Quarter Financial Results
7 May 2026
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
1 May 2026
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once Daily HIV Treatment of Bictegravir Plus Lenacapavir
29 Apr 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito cel
28 Apr 2026
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
22 Apr 2026
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
17 Apr 2026
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
14 Apr 2026
Gilead to Acquire Tubulis Adding Potentially Best in Class Antibody Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
7 Apr 2026